<?xml version='1.0' encoding='utf-8'?>
<document id="16370181"><sentence text="Drug-drug interaction studies on first-line anti-tuberculosis drugs." /><sentence text="The purpose of this study was to carry out drug-drug compatibility studies on pure first line anti-tuberculosis drugs, viz" /><sentence text=", rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol hydrochloride (E)"><entity charOffset="2-12" id="DDI-PubMed.16370181.s3.e0" text="rifampicin" /><entity charOffset="18-27" id="DDI-PubMed.16370181.s3.e1" text="isoniazid" /><entity charOffset="29-30" id="DDI-PubMed.16370181.s3.e2" text="H" /><entity charOffset="33-45" id="DDI-PubMed.16370181.s3.e3" text="pyrazinamide" /><entity charOffset="55-79" id="DDI-PubMed.16370181.s3.e4" text="ethambutol hydrochloride" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e0" e2="DDI-PubMed.16370181.s3.e0" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e0" e2="DDI-PubMed.16370181.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e0" e2="DDI-PubMed.16370181.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e0" e2="DDI-PubMed.16370181.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e0" e2="DDI-PubMed.16370181.s3.e4" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e1" e2="DDI-PubMed.16370181.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e1" e2="DDI-PubMed.16370181.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e1" e2="DDI-PubMed.16370181.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e1" e2="DDI-PubMed.16370181.s3.e4" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e2" e2="DDI-PubMed.16370181.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e2" e2="DDI-PubMed.16370181.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e2" e2="DDI-PubMed.16370181.s3.e4" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e3" e2="DDI-PubMed.16370181.s3.e3" /><pair ddi="false" e1="DDI-PubMed.16370181.s3.e3" e2="DDI-PubMed.16370181.s3.e4" /></sentence><sentence text=" Various possible binary, ternary, and quaternary combinations of the four drugs were subjected to accelerated stability test conditions of 40 degrees C and 75% relative humidity (RH) for 3 months"><entity charOffset="181-204" id="DDI-PubMed.16370181.s4.e0" text="H" /></sentence><sentence text=" For comparison, parallel studies were also conducted on single drugs" /><sentence text=" Changes were looked for in the samples drawn after 15, 30, 60, and 90 days of storage" /><sentence text=" Analyses for R, H, and Z were carried out using a validated HPLC method"><entity charOffset="17-18" id="DDI-PubMed.16370181.s7.e0" text="H" /><entity charOffset="61-61" id="DDI-PubMed.16370181.s7.e1" text="H" /><pair ddi="false" e1="DDI-PubMed.16370181.s7.e0" e2="DDI-PubMed.16370181.s7.e0" /><pair ddi="false" e1="DDI-PubMed.16370181.s7.e0" e2="DDI-PubMed.16370181.s7.e1" /></sentence><sentence text=" The E was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS), as it does not absorb in ultraviolet (UV)" /><sentence text=" All single pure drugs were relatively stable and showed only 3%-5% degradation under accelerated conditions for 3 months" /><sentence text=" However, significant interactions were observed in case of the drug mixtures"><entity charOffset="1-1" id="DDI-PubMed.16370181.s10.e0" text="H" /></sentence><sentence text=" In particular, ternary and quaternary drug combinations containing R and H along with Z and/or E were very unstable, showing 90%-95% and 70%-75% loss of R and H, respectively"><entity charOffset="74-75" id="DDI-PubMed.16370181.s11.e0" text="H" /><entity charOffset="160-161" id="DDI-PubMed.16370181.s11.e1" text="H" /><pair ddi="false" e1="DDI-PubMed.16370181.s11.e0" e2="DDI-PubMed.16370181.s11.e0" /><pair ddi="false" e1="DDI-PubMed.16370181.s11.e0" e2="DDI-PubMed.16370181.s11.e1" /></sentence><sentence text=" In all these cases, isonicotinyl hydrazone (HYD) of 3-formylrifamycin and H was found to be the major degradation product"><entity charOffset="21-43" id="DDI-PubMed.16370181.s12.e0" text="isonicotinyl hydrazone" /><entity charOffset="45-48" id="DDI-PubMed.16370181.s12.e1" text="HYD" /><entity charOffset="53-70" id="DDI-PubMed.16370181.s12.e2" text="3-formylrifamycin" /><entity charOffset="75-76" id="DDI-PubMed.16370181.s12.e3" text="H" /><pair ddi="false" e1="DDI-PubMed.16370181.s12.e0" e2="DDI-PubMed.16370181.s12.e0" /><pair ddi="false" e1="DDI-PubMed.16370181.s12.e0" e2="DDI-PubMed.16370181.s12.e1" /><pair ddi="false" e1="DDI-PubMed.16370181.s12.e0" e2="DDI-PubMed.16370181.s12.e2" /><pair ddi="false" e1="DDI-PubMed.16370181.s12.e0" e2="DDI-PubMed.16370181.s12.e3" /><pair ddi="false" e1="DDI-PubMed.16370181.s12.e1" e2="DDI-PubMed.16370181.s12.e1" /><pair ddi="false" e1="DDI-PubMed.16370181.s12.e1" e2="DDI-PubMed.16370181.s12.e2" /><pair ddi="false" e1="DDI-PubMed.16370181.s12.e1" e2="DDI-PubMed.16370181.s12.e3" /><pair ddi="false" e1="DDI-PubMed.16370181.s12.e2" e2="DDI-PubMed.16370181.s12.e2" /><pair ddi="false" e1="DDI-PubMed.16370181.s12.e2" e2="DDI-PubMed.16370181.s12.e3" /></sentence><sentence text=" In case of RE and RZE mixtures, where H was absent, 3-formylrifamycin was instead the key degradation product"><entity charOffset="39-40" id="DDI-PubMed.16370181.s13.e0" text="H" /><entity charOffset="53-70" id="DDI-PubMed.16370181.s13.e1" text="3-formylrifamycin" /><pair ddi="false" e1="DDI-PubMed.16370181.s13.e0" e2="DDI-PubMed.16370181.s13.e0" /><pair ddi="false" e1="DDI-PubMed.16370181.s13.e0" e2="DDI-PubMed.16370181.s13.e1" /></sentence><sentence text=" Another unidentified peak was observed in the mixture containing RZE" /><sentence text=" Apart from these chemical changes, considerable physical changes were also observed in pure E and the mixtures containing E, viz" /><sentence text=", RE, ZE, RHE, RZE, and RHZE"><entity charOffset="11-27" id="DDI-PubMed.16370181.s16.e0" text="H" /><entity charOffset="25-41" id="DDI-PubMed.16370181.s16.e1" text="H" /><pair ddi="false" e1="DDI-PubMed.16370181.s16.e0" e2="DDI-PubMed.16370181.s16.e0" /><pair ddi="false" e1="DDI-PubMed.16370181.s16.e0" e2="DDI-PubMed.16370181.s16.e1" /></sentence><sentence text=" In addition, significant physical changes associated with noteworthy loss of H and E were also observed in mixtures containing HE and HZE"><entity charOffset="78-79" id="DDI-PubMed.16370181.s17.e0" text="H" /><entity charOffset="128-128" id="DDI-PubMed.16370181.s17.e1" text="H" /><entity charOffset="135-135" id="DDI-PubMed.16370181.s17.e2" text="H" /><pair ddi="false" e1="DDI-PubMed.16370181.s17.e0" e2="DDI-PubMed.16370181.s17.e0" /><pair ddi="false" e1="DDI-PubMed.16370181.s17.e0" e2="DDI-PubMed.16370181.s17.e1" /><pair ddi="false" e1="DDI-PubMed.16370181.s17.e0" e2="DDI-PubMed.16370181.s17.e2" /><pair ddi="false" e1="DDI-PubMed.16370181.s17.e1" e2="DDI-PubMed.16370181.s17.e1" /><pair ddi="false" e1="DDI-PubMed.16370181.s17.e1" e2="DDI-PubMed.16370181.s17.e2" /></sentence><sentence text=" The present study thus amply shows that the four primary anti-tuberculosis drugs, when present together, interact with each other in a multiple and complex manner" /><sentence text="" /></document>